MediWound's 2025 Q2 Earnings Call: Unpacking Key Contradictions on Capacity, Stockpiling, and Regulatory Approvals

Manufacturing capacity and demand, stockpiling strategies for NexoBrid, BARDA funding and manufacturing facility, regulatory approval timeline for manufacturing facility, and BARDA funding and collaboration are the key contradictions discussed in MediWound's latest 2025Q2 earnings call.



Revenue and Product Sales Growth:
- MediWound reported total revenue of $5.7 million for Q2 2025, up 43% sequentially and 43% year-over-year.
- Growth was driven by higher product sales and a more favorable revenue mix.

EscharExPhase III Trial Progress:
- The EscharEx VALUE Phase III trial is actively enrolling patients, with 216 planned participants across the US and Europe.
- Strong interest from both US and European sites and the inclusion of essential wound care products are supporting trial enrollment.

NexoBrid Market Expansion and Manufacturing:
- NexoBrid reported a 52% year-over-year revenue growth in Q2, driven by increased hospital unit orders and ordering centers.
- The planned commissioning of the new manufacturing facility by year-end is expected to support global growth.

Clinical and Regulatory Advancements:
- MediWound is expanding global recognition of EscharEx through clinical collaborations with Convatec and Essity.
- The publication of a post-hoc analysis from a Phase II study supports the key role of EscharEx in wound bed preparation.

BARDA and DoD Funding and Support:
- MediWound received an additional $3.6 million in non-dilutive funding from the DoD for NexoBrid development.
- BARDA's recent RFP includes plans for stockpiling NexoBrid, supporting room temperature-stable formulation, and trauma solutions.